Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Aug 06, 2022 11:07am

171 Views

Post# 34876275

RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

On May 10, 2022 Pfizer announced that it would acquire Biohaven Pharmaceuticals for USD$ 1.6 Billion and would acquire all outstanding shares of Biohaven not already owned by Pfizer for USD$148.50 per share in cash. Biohaven's area of focus is in the treatment of migraine headache.

Conversely ONCY's pelareorep is a 'next-wave' cancer treatment technology which is a platform treatment focused on multiple cancers in combination with multiple existing and developing checkpoint inhibitors, small molecules and adoptive cell therapies.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec